Table 3.
Human trials of 200 mg weekly tafenoquine for prophylaxis against malaria
| Trial 1 | Trial 2 | Trial 3 | Trial 4 | |
|---|---|---|---|---|
| Location | Timor Leste/Australia | Kenya | Ghana | Australia |
| Exposure | 6mo meso-endemic P. falciparum and P. vivax; 6mo post-exposure | 15 weeks exposure to holoendemic P. falciparum | 12 weeks exposure to holoendemic P. falciparum | Experimental P. falciparum blood stages |
| Subjects | Australian soldiers | Resident adults | Resident adults (excluding reproductive age females) | Malaria-naïve adults |
| Number of subjects and armsa | TQ = 462MQ + PQ = 153 | TQ = 61 Placebo = 62 | TQ = 91MQ = 46 Placebo = 94 |
TQ = 12Placebo: 4 |
| Protective Efficacy | Not estimable without placebo; 5 attacks occurred, all post-exposure; 4 in TQ group | 86% | TQ = 87%MQ = 87% | 100% |
| Reference | 87 | 88 | 89 | 71 |
aTQ, tafenoquine administered weekly 200 mg; MQ, mefloquine administered weekly 250 mg; PQ, primaquine administered daily 30 mg for 14 days immediately following travel.